Related Experiment Video
Updated: Jan 14, 2026
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.6K
Challenges in the Patent and Legal Environment for Cell Therapies
1, London, UK. SCS@fabuladocet.net.
Advances in Experimental Medicine and Biology
|October 24, 2025
Summary
Navigating the legal landscape is crucial for cell therapy innovation. This includes understanding regulations for consent, privacy, research, market access, and intellectual property across the USA, EU, and UK.
Area of Science:
- Biomedical Law
- Regulatory Science
- Cell Therapy Development
Background:
- Cell therapy products face complex legal challenges throughout their lifecycle, extending beyond manufacturing and safety.
- These challenges span from initial material procurement to market operations.
Purpose of the Study:
- To outline key legal considerations impacting cell therapy innovation in the USA, EU, and UK.
- To emphasize the strategic importance of addressing legal factors from the inception of cell therapy development.
Main Methods:
- A review of existing legal frameworks in the USA, EU, and UK.
- Analysis of legal issues including consent, privacy, research, market authorization, intellectual property, and commercialization.
Main Results:
- Identified critical legal junctures affecting cell therapy innovation trajectories.
- Highlighted the need for proactive legal strategy throughout the product lifecycle.
Conclusions:
- Legal considerations are integral to the successful development and commercialization of cell therapies.
- Strategic legal planning from the outset is essential for navigating regulatory hurdles and fostering innovation.
Keywords:
ConsentData protectionIntellectual propertyLawLegalMedical tourismPlacing on the marketPrivacyRegulationResearchStem cellscell therapiesMore Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
230
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
230
01:16Cell Lines
10.0K
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
10.0K
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:22iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
01:06Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
00:57Embryonic Stem Cells
4.7K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
4.7K